Metosyn (Fluocinonide)

Fluocinonide penetrates the skin and binds to glucocorticoid receptors inside cells. The drug‑receptor complex then modulates gene expression, increasing anti‑inflammatory proteins while suppressing pro‑inflammatory cytokines, chemokines and adhesion molecules, which collectively dampen the local immune response.

The appropriate dose of Metosyn is determined by the prescribing healthcare professional based on the severity of the condition, the area of skin involved and the treatment duration. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

The safety of fluocinide during pregnancy or lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and discuss alternative therapies if concerns arise.

To request Metosyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Fluocinonide is classified as a high‑potency corticosteroid, offering stronger anti‑inflammatory effects than low‑ or medium‑potency agents such as hydrocortisone. Compared with other high‑potency steroids, its efficacy is similar, but formulation differences (cream, ointment, gel) may influence patient preference and skin tolerability.

Metosyn should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture, heat and direct sunlight. Do not freeze or expose the product to extreme temperatures.

Apply a thin layer of Metosyn to the affected skin area once or twice daily, as directed by the prescriber. Gently rub the medication into the skin until it disappears. Wash hands before and after application unless the hands are the treatment site.

Serious risks include systemic corticosteroid effects such as adrenal suppression, severe allergic reactions, secondary skin infections, and marked skin atrophy leading to striae or telangiectasia. Patients should report signs of unusual bruising, rapid weight gain, persistent fatigue or severe skin changes promptly.

Metosyn is contraindicated in individuals with known hypersensitivity to fluocinide or any formulation component, in untreated bacterial, viral or fungal skin infections, and in patients with severe skin atrophy or rosacea‑like dermatitis. Caution is also advised for children and for use on large body surface areas.